Clinical Outcomes Of Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung Cancer Patients With Brain Metastasis Treated With Erlotinib Versus Gefitinib

被引：0
|
作者：
Saruwatari, K. [1 ]
Saeki, S. [1 ]
Sakamoto, Y. [1 ]
Jodai, T. [1 ]
Sakata, S. [1 ]
Tomita, Y. [1 ]
Nakamura, K. [1 ]
Hirosako, S. [1 ]
Okamoto, S. [1 ]
Ichiyasu, H. [1 ]
Fujii, K. [1 ]
Kohrogi, H. [1 ]
机构：
[1] Kumamoto Univ Hosp, Kumamoto 8556, Japan
来源：
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE | 2017年 / 195卷
关键词：
D O I：
暂无
中图分类号：
R4 [临床医学];
学科分类号：
1002 ; 100602 ;
摘要：
A4583
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Upfront Cranial Radiotherapy Followed by Erlotinib Positively Affects Clinical Outcomes of Epidermal Growth Factor Receptor-mutant Non-small Cell Lung Cancer With Brain Metastases
    Saruwatari, Koichi
    Ikeda, Tokunori
    Saeki, Sho
    Shingu, Naoki
    Imamura, Kosuke
    Komatu, Taiyou
    Ushijima, Sunao
    Maruyama, Hirotaka
    Kashiwabara, Kosuke
    Tomita, Yusuke
    Ichiyasu, Hidenori
    Fujii, Kazuhiko
    Sakagami, Takuro
    ANTICANCER RESEARCH, 2019, 39 (02) : 923 - 931
  • [2] Efficacy of Afatinib, Erlotinib, and Gefitinib on epidermal growth factor receptor (EGFR) mutant non-small cell lung cancer (NSCLC) patients with brain metastasis: a network meta-analysis
    Koo, So-My
    Kim, Ki-Up
    Kim, Yang-Ki
    Uh, Soo-Taek
    EUROPEAN RESPIRATORY JOURNAL, 2018, 52
  • [3] Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in the Treatment of Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung Cancer Metastatic to the Brain
    Jamal-Hanjani, Mariam
    Spicer, James
    CLINICAL CANCER RESEARCH, 2012, 18 (04) : 938 - 944
  • [4] The gefitinib dose reduction on survival outcomes in epidermal growth factor receptor mutant non-small cell lung cancer
    Sung Hoon Sim
    Bhumsuk Keam
    Dong-Wan Kim
    Tae Min Kim
    Se-Hoon Lee
    Doo Hyun Chung
    Dae Seog Heo
    Journal of Cancer Research and Clinical Oncology, 2014, 140 : 2135 - 2142
  • [5] The gefitinib dose reduction on survival outcomes in epidermal growth factor receptor mutant non-small cell lung cancer
    Sim, Sung Hoon
    Keam, Bhumsuk
    Kim, Dong-Wan
    Kim, Tae Min
    Lee, Se-Hoon
    Chung, Doo Hyun
    Heo, Dae Seog
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2014, 140 (12) : 2135 - 2142
  • [6] Epidermal growth factor receptor polymorphisms and clinical outcomes in non-small-cell lung cancer patients treated with gefitinib
    Liu, G.
    Gurubhagavatula, S.
    Zhou, W.
    Wang, Z.
    Yeap, B. Y.
    Asomaning, K.
    Su, L.
    Heist, R.
    Lynch, T. J.
    Christiani, D. C.
    PHARMACOGENOMICS JOURNAL, 2008, 8 (02): : 129 - 138
  • [7] Epidermal growth factor receptor polymorphisms and clinical outcomes in non-small-cell lung cancer patients treated with gefitinib
    G Liu
    S Gurubhagavatula
    W Zhou
    Z Wang
    B Y Yeap
    K Asomaning
    L Su
    R Heist
    T J Lynch
    D C Christiani
    The Pharmacogenomics Journal, 2008, 8 : 129 - 138
  • [8] Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib
    Riely, GJ
    Pao, W
    Pham, DK
    Li, AR
    Rizvi, N
    Venkatraman, ES
    Zakowski, MF
    Kris, MG
    Ladanyi, M
    Miller, VA
    CLINICAL CANCER RESEARCH, 2006, 12 (03) : 839 - 844
  • [9] Brain surgery for epidermal growth factor receptor-mutant non-small-cell lung cancer with brain metastases
    Lee, H. H.
    Huang, M-Y.
    ANNALS OF ONCOLOGY, 2018, 29 : 161 - 161
  • [10] Clinical Value of Upfront Cranial Radiation Therapy in Osimertinib-Treated Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung Cancer With Brain Metastases
    Yu, Fan
    Ni, Jianjiao
    Zeng, Wanqin
    Zhou, Yue
    Guo, Tiantian
    Zeng, Ya
    Zhao, Yang
    Li, Shuyan
    Li, Yida
    Yang, Xi
    Zou, Liqing
    Wang, Shengping
    Liu, Quan
    Li, Yuan
    Chu, Li
    Chu, Xiao
    Ye, Luxi
    Yu, Wen
    Zhu, Zhengfei
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2021, 111 (03): : 804 - 815
12345